REPORT BY THE BOARD OF DIRECTORS ON EVENTS WITH AN ESSENTIAL EFFECT ON THE STATE OF HERANTIS PHARMA PLC THAT HAVE OCCURRED AFTER THE PUBLICATION OF THE HALF-YEAR FINANCIAL REPORT 1 JANUARY–30 JUNE 2026

The Board of Directors of Herantis Pharma Plc (the "**Company**") hereby states, as its report pursuant to Chapter 5, Section 21, Subsection 2, Paragraph 4 of the Finnish Companies Act, that events with an essential effect on the state of the Company that have occurred after the publication of the Half-Year Financial Report 1 January–30 June 2026 (published on 20 August 2026) have been announced in the company releases published by the Company and are available on the Company's website at https://herantis.com/news-events/releases/.

On 24 November 2026, the Company announced that it carries out an accelerated bookbuilding to raise EUR 15–20 million. In addition, on 25 November 2026, the Company announced the results of the accelerated bookbuilding.

The releases published after the publication of the Half-Year Financial Report 1 January–30 June 2026 are available on the Company's website at the above-mentioned address.

In Helsinki on 25 November 2026

HERANTIS PHARMA PLC

The Board of Directors